The Winship Cancer Institute (Winship) has solicited extensive Input from both external and internal advisory groups and leadership committees for the planning and evaluation of its current progress, continued advancement, and the establishment of future goals and objectives. In the last reporting period, Strategically composed internal and external committees have enabled Winship to elevate the science it performs. The internal and external mechanisms discussed in this section provide essential guidance on all aspects of Winship, and include the following groups: External Planning and Evaluation: External Advisory Board (EAB), External Administrative Advisory Board, and External Clinical Trials Advisory Boards;and Internal Planning and Evaluation: Winship Internal Advisory Board, Winship Executive Committee, Scientific Research Council, Shared Resource Directors Meeting, Shared Resource Oversight Committee, Membership Committee, Shared Resource Allocation Committee, Space Resource Allocation Committee, Administrative Council, and Winship Clinical Council. Guidance and direction gathered from these many committees has been critical to the advancement of the Winship Cancer Institute. The input from these groups played a major role in the development of the 2010-2015 Winship Strategic Plan. That document has provided Winship a roadmap during the funding cycle proposed in this application. The funds requested in addition to committed institutional funds will provide support for these important advisory endeavors.
The Planning and Evaluation process has been instrumental in Winship's many successes. Each advisory structure works to ensure that Winship's priorities are understood and strategically managed to allow the cancer center to continue to develop and achieve a comprehensive set of goals.
|Berg, Carla J; Stratton, Erin; Esiashvili, Natia et al. (2016) Young Adult Cancer Survivors' Experience with Cancer Treatment and Follow-Up Care and Perceptions of Barriers to Engaging in Recommended Care. J Cancer Educ 31:430-42|
|Patel, Kirtesh R; Chowdhary, Mudit; Switchenko, Jeffrey M et al. (2016) BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Res 26:387-94|
|Horton, John R; Liu, Xu; Gale, Molly et al. (2016) Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds. Cell Chem Biol 23:769-81|
|Yoshida, Michihiro; He, Peijian; Yun, C Chris (2016) Transgenic Expression of Human Lysophosphatidic Acid Receptor LPA2 in Mouse Intestinal Epithelial Cells Induces Intestinal Dysplasia. PLoS One 11:e0154527|
|Bajpai, R; Matulis, S M; Wei, C et al. (2016) Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Oncogene 35:3955-64|
|Bonner, Michael Y; Karlsson, Isabella; Rodolfo, Monica et al. (2016) Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo. Oncotarget 7:12857-68|
|Owonikoko, Taofeek K; Zhang, Guojing; Kim, Hyun S et al. (2016) Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. J Transl Med 14:111|
|Xiao, Canhua; Miller, Andrew H; Felger, Jennifer et al. (2016) A prospective study of quality of life in breast cancer patients undergoing radiation therapy. Adv Radiat Oncol 1:10-16|
|Oliver, Daniel E; Patel, Kirtesh R; Switchenko, Jeffrey et al. (2016) Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma. Melanoma Res 26:35-41|
|Liu, Min; Wang, Hongyan; Lee, Solah et al. (2016) DNA repair pathway choice at various conditions immediately post irradiation. Int J Radiat Biol 92:819-822|
Showing the most recent 10 out of 210 publications